GSK scores major trial win with potential multiple myeloma b...

GlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal DREAMM-2 trial in relapsed multiple myeloma.

GSK hires former Genentech expert for AI unit

FDA reviews Sanofi's multiple myeloma drug isatuximab

The FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for a tussle with Johnson & Johnson’s blockbuster Darzalex.

FDA clears Karyopharm’s myeloma drug despite advisory panel ...

Janssen to develop Darzalex successor with Genmab

Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it hopes will outperform its already-marketed Darzalex in multiple myeloma, and oth

EU regulators to fast-track Janssen's multiple myeloma CAR-T

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.